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SUMMARY
The quantitative evaluation of the reactivity in 
human phytohaemagglutinin-stimulated lymphocyte cultures 
was studied using a whole blood technique. Cells were 
cultured for 22 hours in various concentrations of PHA, 
and by measuring the amount of incorporation of tritium 
labelled leucine into the proteins synthesised, a dose 
response curve could be drawn up for each donor. The 
patients studied fell into three main categories.
(a) 22 patients with brain tumours. Depressed protein 
synthesis was detected in many of these when com­
pared to 35 normal healthy controls, and also to 20 
patients with various chronic neurological diseases.
A 3-day culture technique was developed to test the 
effect of sera from patients with brain tumours, and 
other neurological complaints, on normal lymphocytes. 
No serum blocking factor was found.
(b) Patients undergoing practolol therapy. Impaired 
T-cell function was seen in all patients whether 
they manifested adverse reactions to the drug in vivo 
or not. Normal lymphocytes were cultured for 2 days 
in the presence of various P-blocking drugs, then 
their response to PHA was measured. Only propranolol 
was seen to cause depression of protein synthesis.
(c) 31 patients with epilepsy who were taking various
anticonvulsant drugs, including phenytoin. Low 
responses were seen in all patients on anticonvulsants 
when compared to 35 normal healthy controls.
ABBREVIATIONS
ATP Adenosine triphosphate
B-lymphocyte Non-thymus derived lymphocyte
cAMP Cyclic adenosine 3', 51-monophosphate
cGMP Cyclic guanosine 3', 5'-monophosphate
C3 The third component of complement
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IgG Immunoglobulin G
IgM Immunoglobulin M
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s.d. Standard deviation
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T-lymphocyte Thymus derived lymphocyte
tRNA Transfer RNA
X Mean value
INTRODUCTION
Knowledge of the workings of the immune system has 
expanded enormously in recent years. Early workers in 
this field concentrated on serological reactions, basing 
their concepts on historical observations that patients 
who survived certain infectious diseases were protected 
from subsequent infection. This ability to ward off 
infections was considered to be a function purely of 
humoral substances only. Attention was drawn to the 
possible role of cells in immunity by the great Russian, 
Eli Metchnikoff, who, having resigned his professorship 
at Messina in 1882, began to study the behaviour of 
microscopic marine organisms. From his work, a theory of 
phagocytosis arose, and it is a reflection of the 
ignorance at that time, that two different camps of 
immunology evolved. We thus have the beginning of modern 
immunology in which we now know that both cellular and 
humoral factors are involved.
In the late nineteenth century, Robert Koch described 
a modified reaction to tuberculosis in animals which had 
previously been exposed to infection. He observed that 
the inoculation of cultures of bacilli into a tuberculous 
guinea pig caused the appearance of an inflamed area 
after 1 to 2 days, whereas little reaction occurred in 
normal animals similarly injected (Koch, 1890). This 
Koch phenomenon could be elicited with living, killed, or 
glycerine extracts of tubercle bacilli. Further studies 
of the skin reaction taking place demonstrated that it 
differed from humoral immune reactions in (a) its time of 
onset, (b) its dermal characteristics, and (c) its
histological components. The term,delayed hypersensitivity, 
was applied to this skin reaction and it was initially 
studied with infectious agents such as tuberculosis, 
hydatid disease, coccidioidomycosis, histoplasmosis and 
leprosy. In 1928 Dienes demonstrated that a similar reaction 
could be elicited to proteins other than bacterial.
The characteristic skin changes in a delayed hyper­
sensitivity reaction include oedema with perivenous 
mononuclear cell infiltration of lymphocytes, macrophages 
and epithelial cells. A variety of evidence began to 
accumulate which showed that the lymphocyte was the cell 
responsible for this reaction. This rested on the facts 
that lymphocytes are always present in the lesion, and 
that the reaction may be transferred by living lymphoid 
cells in syngeneic animals and not by serum. The passive 
transfer of contact sensitivity by Landsteiner and Chase 
(1942) and of sensitivity to tuberculin by Chase (1945) 
demonstrated that viable cells from peritoneal exudates, 
lymph nodes and spleens could mediate this reaction.
Despite the early attention paid to the cellular 
factors in immunology, the explosion of knowledge of 
cellular immune mechanisms only took place in the middle 
of this century. Our present knowledge of cellular immune 
function grew out of the ability to study cells in tissue 
culture•
The central importance of the lyirqphocyte was 
established largely by the work of Gowans (1966), who, 
using a radioactive label to follow their fate in vivo, 
showed the presence of a pool of recirculating leukocytes 
which pass from the blood into lymph nodes, thymus, spleen
and bone marrow, by way of the major lymphatic channels, 
such as the thoracic duct. In general, the lymphocyte is 
a spherical cell with a large round nucleus and a narrow 
rim of cytoplasm which appears to be lacking endoplasmic 
reticulum, and a Golgi apparatus, structures normally 
associated with protein synthesis, and secretion. In 
this group of cells,heterogeneous with respect to life­
span, origin and function, two main morphological types 
appear to exists small lymphocytes with an overall diameter 
of 7-8 microns, making up 92% of all lymphocytes; and large 
lymphocytes with a diameter of around 12 microns.
Before 1960, the only known activity of small lympho­
cytes was motility, and it was generally suggested that 
the small lymphocytes did not themselves perform 
physiologically, but that they served as precursors of 
other cell types. As techniques and experimental skills 
became more advanced, the small lymphocyte begem to emerge 
as the primary cell involved in the defence of the body, 
being responsible for recognition of foreign emtigens, 
and for initiating reactions against them. Lymphocytes 
were shown to be involved in antibody production emd in 
graft rejection, as well as delayed hypersensitivity 
reactions.
The discovery that the thymus was involved in the 
development of the immune system (Miller, 1961; Archer, 
Pierce, Papermaster and Good, 1962), proved to be of 
central importance. From this came the finding that 
lymphocytes associated with the thymus were not capable 
themselves of making antibody, but co-operated with other 
non-thymus derived lymphocytes to do so (Davies, 1969;
Miller and Mitchell, 1969). These cells were christened 
T-cells by Roitt, Greaves, Torrigiani, Brostoff and 
Playfair (1969). The non-thymus derived lymphocytes they 
called B-cells due to the discovery in chickens of the 
Bursa of Fabricius, a lymphoid organ which is responsible 
for the development of immunocompetance in cells destined 
to make humoral antibody. The equivalent of the bursa in 
man and other mammals has not yet been clearly defined, 
although gut-associated lymphoid tissue such as the tonsils, 
appendix and Peyer1s patches have been nominated as 
possible candidates.
On stimulation by antigen both populations undergo 
morphological changes (Fig. 1). The B-lymphocytes develop 
into the plasma cell series, and so are responsible for the 
production and secretion of immunoglobulins, and for the 
formation of germinal centres within the primary nodules 
of lymphoid tissues. T-lymphocytes transform to lympho­
blasts which are responsible for all cell mediated immune 
reactions including graft rejection, delayed hyper­
sensitivity, tuberculin test reactions and defence against 
viral infections and some bacteria. T-lymphocytes are 
also known to co-operate with B-cells for the production 
of antibodies to certain antigens. In this case the T-cell 
is probably releasing a specific factor which activates 
B-lymphocytes either directly or through the participation 
of a third cell, a macrophage.
Various subsets of T-lymphocytes have recently been 
described: “helper"-cell - a thymus derived cell whose 
presence is required both in vivo and in vitro for the 
production of normal levels of antibody by B-lymphocytes
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line 11 should read:- " e.g. in the mouse,
helper cells are phenotypically Lyl+W
to certain antigens known as thymus dependent antigens, 
and to haptens: "suppressor"-cell - a T-cell capable of 
regulating the magnitude of antibody production by inhibit­
ing the expression of the various types of B-cells reactive 
to a particular antigen: "killer"-cell - a T-lymphocyte 
which in vitro is cytotoxic to cell cultures. As well as 
being classified according to function, these sub-classes 
may be identified phenotypically on the basis of antigenic 
surface markers, e.g. helper cells are phenotypically Lyl+ ,
cytotoxic and suppressor cells are Ly2+ and Ly3+ , and
+ + + immature cells Lyl , Ly2 and Ly3 •
Studies in laboratory animals using well defined 
antigens, and under controlled conditions, have shown 
that certain diseases involving the immune system can be 
transferred by living lymphoid cells. Research arising 
out of studies of these cells in tissue culture have 
opened up many avenues for the study of possible human 
immunological disorders. These tissue culture, in vitro, 
techniques developed from the studies of Rich and Lewis 
(1932) on the movement of peritoneal macrophages, and on 
the observations of Hungerford, Donnelly, Nowell and 
Beck (1959) on the morphological changes that occurred in 
human peripheral blood lymphocytes on culture with an 
extract of the red kidney bean, Phaseolus vulgaris.
At the present time there are many techniques for 
studying the activity of lymphocytes in culture. Most of 
these are based on the fact that sensitised lymphocytes 
interact with their corresponding antigen to produce 
lymphokines (Dumonde, Wolstencroft, Panayi, Matthew,
Morley and Howson, 1969), soluble factors which cause a
variety of effects including lymphocyte transformation, 
inhibition of migration of macrophages and peripheral 
blood lymphocytes, activation of macrophages, chemotaxis 
of mononuclear cells, skin reaction, cytotoxicity and 
inhibition of virus multiplication. In vitro techniques 
have therefore been developed to give accurate measurement 
of the lymphokine activity, and thus a measurement of the 
degree of sensitisation of a population of lymphocytes to 
a particular antigen.
One technique which has particular advantages is 
lymphocyte protein synthesis. This technique involves 
the measurement of protein produced in preparation for 
mitosis of lymphocytes in contact with either non-specific 
mitogenic substances, e.g. plant lectins; antigen against 
which the lymphocyte donor has been previously immunised: 
or lymphocytes from a genetically foreign individual. 
Changes in protein synthesis can be detected in lymphocytes 
within hours of such contact, and measurement of this 
phenomenon has been used to detect cell mediated immunity 
(Waithe and Hirschhorn, 1971; Rosenberg and Levy, 1972).
By the addition of radioactively labelled amino acids to 
the culture medium of stimulated cells, it is possible, 
after a specific time interval, to measure the amount of 
incorporation into either the proteins or DNA, synthesised 
by those cells.
Phytohaemagglutinin (PHA), an extract of Phaseolus 
vulgaris, was the first non-specific mitogen to be 
demonstrated (Hungerford et al, 1959; Nowell, 1960).
Since then, many other lymphocyte mitogens have been found, 
some of which are extracts from other plants, e.g.
Concanavelin A (Douglas, Kamin and Fudenberg, 1969) and 
Pokeweed mitogen (PWM) (Fames, Barker, Brownhill and 
Fanger, 1964); and some which are bacterial products, e.g. 
Staphylococcal culture filtrate (Ling, Spicer, James and 
Williamson, 1964) and Streptolysin S (Hirschhorn,
Schreibman, Verbo and Gruskin, 1964). Also included are 
antibodies against cellular antigens (Grasbeck, Nordman 
and De La Chapelle, 1964) and against globulins on the 
cell surface (Adinolfi, Gardner, Gianelli and McGuire,
1967) and various chemicals and ions.
Blastogenesis with non-specific mitogens occurs 
without prior sensitisation, and equally well in both 
adult and cord blood (Lindahl-Kiessling and Book, 1964). 
Unlike the stimulation with antigen, where only a small 
fraction of the cells respond (Elves, Roath and Israels,
1963; Pearmain, Lycette and Fitzgerald, 1963), PHA trans­
forms a major proportion of the T-lymphocytes. Additionally, 
some B-cells are affected, although their response appears 
to be T-dependent. The picture is emerging that helper 
T-cells are preferentially stimulated by PHA, and 
suppressors by Con A (Roitt, 1977). PWM activates both 
T and B lymphocytes, while lipopolysacharide (in the 
mouse at least) is a B-cell mitogen. Most of these 
mitogenic stimulants have a high molecular weight and a 
relatively complex structure and, as yet, the molecular 
basis for their mitogenic activity is unknown.
Although the sequence of morphological changes in 
transformation is well established (Elves, Chapman, Gough 
and Israels, 1964; Polliack, Touraine, De Harven, Lampen 
and Hodden, 1976), the metabolic changes which accompany
and permit morphogenesis are still under investigation.
It has been shown (Powell and Leon, 1970; Allan,
Auger and Crumpton, 1971) that the first step essential 
for activation is the interaction of the carbohydrate 
binding site of the lectin with the cell surface glyco­
protein, or glycolipid receptor. The exact chemical nature 
of the receptor site is unknown, but work by Toyshima,
Fukuda and Osawa (1972) suggests the existence of distinct 
specific lymphocyte receptors for PHA and Con A. This was 
confirmed by Faguet (1977) who further suggested that the 
majority of lymphocyte membrane receptors for PHA and Con A 
are "spare" or redundant since as little as 3-15% receptor 
occupancy by the ligand was sufficient for maximal cell 
response (Novogrodsky, Biniaminov, Ramot and Katchalski, 
1972; Faguet, 1976). It also appears that the stimulation 
of lymphocytes by antigen or lectins usually, and perhaps 
always, requires that the receptors be crosslinked by 
multivalent ligands (Greaves and Janossy, 1972; Allan and 
Crumpton, 1973). Recent studies on the distribution and 
mobility of lymphocyte surface receptors, and the 
modulation of receptor movement by lectin reagents, suggests 
that the surface receptors may have a common anchorage 
system, consisting of microfilaments and microtubules 
within the cell (Petris and Raff, 1973; Yahara and Edelman, 
1973). It has been proposed (Edelman, Yahara and Wang,
1973) that such a system may also serve the function of 
regulating and transducing a variety of external signals 
to the appropriate intracellular messengers. Binding is 
not itself sufficient to trigger DNA synthesis (Hellstrom, 
Dillner, Hammarstrom and Perlmann, 1976), but causes a
number of biochemical changes.
Within the first minute, and thus preceding other 
known metabolic alterations in lectin stimulated cells, 
activation of the enzyme adenylate cyclase, causes a small, 
but consistent, increase in cyclic adenosine monophosphate 
(cAMP) with a maximal response obtained after 5-15 minutes 
(Smith, Steiner and Parker, 1971; Lyle and Parker, 1974; 
Parker, Sullivan and Wedner, 1974) followed by a decline 
to control values after 1-2 hours.
This increase leads to a selective activation of one,
or a group of protein kinases, under the control of cAMP,
and of membrane metabolism and transport, allowing
++increased uptake of Ca and other essential nutrients 
into the cytoplasm (Allwood, Asherman, Davey and Goodford, 
1971; Whitney and Sutherland, 1972). Parker (1977) has 
shown that high concentrations of cAMP (10-100 ^M) markedly 
inhibits the DNA synthetic response to PHA, whereas in 
low doses, it can stimulate mitogenesis, although the 
magnitude of change is only 2-3 fold, and much less than 
the 50-100 fold response seen with PHA or Con A (Hirschhorn, 
Grossman and Weissraan, 1970; Smith, Steiner, Newberry and 
Parker, 1971).
The exact role of cAMP is poorly understood, but its 
importance in lymphocyte activation, both as a positive 
and a negative modulatory agent is clear. Work in several 
laboratories indicates that cAMP is also involved in the 
production of lymphokines by stimulated lymphocytes 
(Kishimoto, Miyake, Nishizawa, Watanabe and Yamamura, 1975). 
Smith et al (1971) and Hadden, Hadden, Haddox and Goldberg 
(1972) implicate cGMP as well as cAMP as intracellular
regulators of mammalian cell growth and differentiation. 
Intracellular levels of cGMP have been shown to increase 
after human peripheral lymphocytes have been induced to 
proliferate by Con A or PHA (Hadden et al, 1972), and have 
been shown to reverse the inhibitory effect of cAMP 
(Bourne, Lichtenstein, Melmon, Henney, Weinstein and 
Shearer, 1974). Bourne et al (1974) also suggested that 
cAMP and cGMP may act in a "push-pull" fashion to regulate 
lymphocyte functions. The importance, however, of cGMP 
in early phases of human T-cell activation is controversial 
(Wedner, Dankner and Parker, 1975) although a good case 
exists for a modulatory role of cGMP in responses of 
murine B-lymphocytes to liposaccharides (Watson, 1975? 
Weinstein, Segal and Melmon, 1975).
During the first hour of the response, PHA and Con A 
produce a 2-10 fold increase in calcium ion uptake, with 
the most marked changes occurring during the first few 
minutes (Parker, 1977; Allwood et al, 1971; Whitney et al, 
1972). This change in membrane permeability may be related 
to the change in cGMP and cAMP levels, but more work is 
needed to clarify this.
In addition to Ca++ and the cyclic nucleotide 
changes, the possible role of microtubules and micro­
filaments in the regulation of lymphocyte function must 
be considered. Most eukaryotic cells contain a rich 
array of microtubules and microfilaments in close 
association with the plasma membrane. Morphological 
studies (Bryan, 1974; Wessels, Spooner, Ash, Bradley, 
Ludvena, Taylor, Wrenn and Yamada, 1971) suggest that 
these structures can extend from the cell membrane into
the cytoplasm, and thus either, or both, could be a part 
of a mechanical transduction system through which 
perturbations exerted at the lymphocyte surface are con­
veyed to the interior of the cell.
Which of these early alterations is responsible for 
transmission of mitogenic signal to the nucleus is not 
yet clear (Fig. 2).
The amino acid uptake of responding lymphocytes is 
seen to increase 2-4 fold, 30-60 minutes after contact with 
PHA or Con A (Parker, 1977). Later RNA (Cooper and Rubin, 
1965; Mueller and La Mahieu, 1966) and protein (Bach and 
Hirschhorn, 1963; Kay and Komer, 1966) synthesis accelerate, 
and the activities of several amino acids are increased. 
Protein production takes place mainly in the first two 
hours (Bach and Hirschhorn, 1963) with not much more by 
24 hours. Synthesis of this protein takes place on the 
ribosomes, which are found bound to the endoplasmic 
reticulum in the cytoplasm. The ribosomes consist of 
around 40% protein and 60% RNA, and this RNA, termed 
messenger or mRNA acts as a template upon which new proteins 
are built. DNA is required as the primer in the synthesis 
of mRNA, thus the specific organisation and alignment of 
amino acids in the polypeptide chain of a protein is a 
direct reflection of the base sequence in the gene (DNA). 
Transfer, or tRNA is responsible for carrying a specific 
amino acid to the site for protein synthesis, and it 
appears there is at least one specific tRNA for each of 
the twenty different amino acids (Fig. 3). Energy require­
ments for DNA and protein synthesis are sustained by 
glycolysis (Cooper, Barkham and Hale, 1961).
Fig. 2 Some early events in mitogenesis.
(1) Binding of ligand to cell surface 
receptors *
(2) Receptors are assumed to interact directly 
or indirectly with an assembly of sub- 
membranous proteins including (///////) 
microfilaments and (oooooo) microtubules, 
which in turn G§n &§ in various states
of association and disassociation.
(3) Transport of calcium ions.
(4) Activation of cyclase systems for cGMP 
and cAMP.
The proximate surface-to-nuclear signal is not
known.
Ligand
Cytoplasm
oooooooo 0000 \  >
///////////////////// V
guanine cyclase 
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Diagrammatic representation of some early events in 
mitogenesis.
Fig, 3 Intracellular actions involved in synthesis 
of protein in an animal cell.
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A wide variety of specific proteins are synthesised, 
among them albumin, transferrin, lgG, lipoprotein and 
interferon (Lucas, 1971). Also produced are many non­
antibody immune effector factors such as lymphotoxin (LT) 
(Granger and Kolb, 1968), migratory inhibitory factor (MIF) 
(Bennett and Bloom, 1968) and mitogenic factor 
(Wolstencroft and Dumonde, 1970). The chemical character­
isation of these synthesised proteins was done by Turner 
and Forbes in 1966. Active DNA synthesis occurs about 48 
hours after initiation of the PHA response, and shortly 
after this the cells enter mitosis (Weinstein, Melmon and 
Segal, 1976).
Mitosis of sensitised lymphocytes after contact with 
specific antigen, has been used as an assay for the presence 
of cellular immunity, and for detecting foreign histocompat- 
ability antigens for several years (Bach and Hirschhorn, 
1964: Ling, 1968; Qppenheim, Leventhal and Hersh, 1968).
The degree of transformation can be measured either by 
morphological examination or by uptake of radioactive 
labelled thymidine. Many culture systems have been devised 
using leukocytes (Hungerford et al, 1959: Nowell, 1960), 
purified lymphocytes (Cooper and Rubin, 1965: Schellekens 
and Eijsvoogel, 1968: Polliack et al, 1976) or whole blood 
(Junge, Hoekstra, Wolfe and Deinhardt, 1970: Pauly, Sokal 
and Han, 1973: Heitman, 1967: Park and Good, 1972). The 
use of a whole blood culture technique offers a number of 
advantages as well as considerable savings in time, cost 
and volume of blood required. By eliminating the cumber­
some and often complex steps required for preparing pure 
lymphocyte suspensions, one of the major sources of
technical variability and error responsible for poor 
reproducibility is removed.
The main difference between a culture of whole blood 
and one of purified lymphocytes is the presence of large 
numbers of erythrocytes and granulocytes in the culture. 
Knight and Ling (1969) have shown that the addition of 
erythrocytes does not alter the response of purified 
lymphocytes to staphylococcal filtrate, and Junge et al 
(1970) even found a generally better and prolonged 
lymphocyte growth rate in comparison to pure lymphocyte 
cultures. This inproved growth rate may be due to the 
dense red cell button acting as a type of "feeder" system 
(Pauly et al, 1973) which supports the buffy coat of 
leukocytes and maintains a desirable in vitro environment 
for lymphocyte activation. Another explanation proposed 
is that PHA adsorbed on erythrocyte membranes, is in a 
particularly favourable steric configuration or local 
concentration to stimulate lymphocytes, although direct 
attempts to stimulate lymphocytes with PHA attached to 
erythrocyte membranes have been successful only at very 
high PHA or erythrocyte concentrations (Kay, 1971; Johnson, 
Fink and Ziff, 1972). This would suggest that perhaps the 
membrane alone is the inportant feature and that exchange
of information between cells is not required.
14The C-thymidine uptake by purified PHA-stimulated 
lymphocytes is not significantly altered by the addition 
of granulocytes (Schellekens and Eijsvoogel, 1968), but 
responses to antigens are usually higher in lymphocyte 
cultures containing other white cell elements than in 
cultures of lymphocytes purified by cotton wool or glass
bead column filtration (McFarland, 1969). The addition 
of monocytes to purified lymphocyte populations can 
increase the mitogen-induced proliferation (Oppenheim et al, 
1968; Hollister and Jarrett, 1978). The exact role played 
by macrophages is not yet understood, but evidence suggests 
a synergism exists between lymphocytes and macrophages in 
lymphocyte activation by antigens in culture (Seeger and 
Oppenheim, 1970). There is good cytological evidence 
(McFarland, Heilman and Moorhead, 1966) that lymphocytes 
form aggregates around macrophages, particularly in the 
presence of a stimulant. The lymphocytes attach to the 
macrophages by means of a uropod, and this contact is 
often maintained over a prolonged period. It has been 
observed that the most rapidly growing cells in PHA- 
stimulated cultures are found within cell aggregates, while 
a higher proportion of those outside aggregates show fewer 
signs of activation (Ling and Kay, 1975). Macrophages 
appear to be superior to monocytes in performing this 
synergistic role (Hanifin and Cline, 1970).
The effect of autologous serum present in whole 
blood cultures must be considered. At blood dilutions 
required for eliciting maximal lymphocyte responses, 
enough autologous plasma is present to support good lympho­
cyte viability and reactivity, and avoids the need for 
unautologous supplements to the medium which may introduce 
artifactual errors (Ling, 1968). However, a vast array 
of reports have been published describing non-antigenic 
specific suppressive factors present in serum (Tomasi,
1977), which may affect the response to mitogens by 
either competing with sites on the cell surface for
stimulant, or by directly suppressing the cellular response. 
Many of these substances have been reasonably well 
characterised chemically (Cooperband, Nimberg, Schmid and 
Mannick, 1976) but it must be remembered that this inform­
ation has been derived from in vitro systems, and whether 
data extrapolated from these studies can be applied in vivo 
is questionable.
The response of lymphocytes to PHA may be affected 
by many factors. Drugs such as quinine (Thong and Ferrante,
1978), phenobarb (Park and Brody, 1971), and aspirin 
(Pachman, Esterly and Peterson, 1971) all have been shown 
to suppress DNA synthesis in the presence of PHA, although 
no decrease in cell viability was found. Pachman shows, 
however, that the effect on RNA and protein synthesis of 
stimulated lymphocytes was less pronounced. Age is another 
important factor. Low responses are obtained with cells 
of the very young and of the very old, in agreement with 
the more comprehensive studies in animals (Hagen and 
Fr^lund, 1973). Relatively low responses have been found 
for young people (under 26 years old) compared to older 
adults (Pentycross, 1969), however decreased PHA responsive­
ness is most marked in old age, particularly beyond the 
age of 80 years (Hallgren, Buckley, Gilbertson and Yunis, 
1973; Fernandez, McSween and Langley, 1976; Lavanchy and 
Rosenthal, 1978), where there is a general decline in 
cellular immune activity. Conditions within the test 
itself, such as cell number, surface area, duration of 
culture are also important, and once a technique has been 
decided it must be strictly adhered to if meaningful com­
parisons are to be made.
Delayed cutaneous hypersensitivity is considered the 
best in vivo method for assessment of cellular immunity 
(Rocklin and David, 1976), and therefore it is often use­
ful to correlate results from in vitro methods with this 
in vivo test. Kerby (1968) found that the degree of 
lymphocyte transformation in response to tuberculin anti­
gen correlated with the intensity of the cutaneous reaction 
to the same antigen, in the same donor. A correlation 
between cutaneous reactivity and in vitro lymphoblast 
response was also shown by Hinz, Daniel and Baum (1970) 
but no correlation was seen with antibody production and 
skin testing. Chaparas, Sheagren, DeMeo and Hedrick 
(1970) on the other hand could find no association between 
the skin reaction in vivo and lymphoblastic transformation 
in vitro. Since these tests are carried out using various 
methods, and having differing culture conditions, it may 
be that each is measuring a slightly different function of 
lymphocyte response.
The purpose of this thesis is to present the results 
of applying the in vitro technique of lymphocyte protein 
synthesis to a large number of patients with various 
neurology-related diseases, and to controls. The diseases 
were studied because immune function may be involved in the 
pathogenesis. The evidence which led to the selection of 
these particular diseases will be discussed later in this 
work.
METHODS
Patients
The studies reported in this thesis were done on 
patients suffering from various neurological complaints. 
These patients were drawn mainly from the neurological 
and neurosurgical wards, and the outpatient clinics of 
the Institute of Neurological Sciences in Glasgow.
Patients were also studied from the Epilepsy Centre, 
Quarrier's Homes, Bridge of Weir, Renfrewshire and from 
the outpatient clinics of the Victoria Infirmary, Glasgow.
Techniques 
Blood Sampling
Blood samples were taken by venepuncture from an 
antecubital vein after cleaning the area with spirit.
If lymphocyte protein synthesis was to be measured the 
syringe used was wetted with preservative-free heparin 
(1,000 units/ml, Evans Medical) and the blood collected 
in a sterile plastic universal container. If serum was 
required the blood was collected in plain glass tubes 
which were centrifuged when clotted and the serum stored 
at -20°C until required.
Cutaneous Reactivity
Skin testing was done by an intradermal injection 
of 0.1 ml of antigen into a cleaned area on the volar 
aspect of the arm. The antigens used were: 5 units of 
streptokinase/streptodornase (Lederle Laboratories,
American Cyanamid Company); 0.5% Candida albicans (Bencard); 
and 10 units PPD (purified protein derivative of tuberculin,
Evans Medical). The results were examined at 6, 24 and 48 
hours, and the product of two maximal diameters measured.
The test was considered positive when the indurated area 
was 1 cm or greater in diameter.
Lymphocyte Protein Synthesis
Peripheral blood lymphocyte protein synthesis was 
measured by a modification of a whole blood technique 
(Pauly, Sokal and Han, 1973). Essentially 10-12 mis 
venous blood was taken as previously described. A 
lymphocyte count was then done, using an Improved Neubauer 
Counting Chamber, and the concentration of cells adjusted 
with RPMI 1640 tissue culture medium (Gibco Europe) con­
taining 50 units of penicillin and 50 ng streptomycin/ml,
6to give approximately 1 x 10 lymphocytes per culture 
tube. To this cell suspension was added tritiated leucine 
(Radiochemical Centre, Amersham) specific activity 19 curies/ 
mmol, to give 1 jiCi of tritiated leucine per culture.
After careful mixing, the cell suspension was pipetted 
in 3 ml aliquots into 16 x 120 mm glass culture tubes con­
taining 0.1 ml of a given concentration of purified phyto- 
haemagglutinin (Burroughs Wellcome). In general seven 
dilutions of PHA were used, giving final concentrations 
of 16.66, 8.33, 2.08, 1.04, 0.26, 0.065 and 0.016 jig/ml.
The culture tubes were tightly capped and placed in an 
upright position in an incubator at 37°C. After 22 hours 
the tubes were removed and the cells washed in 10 mis 
normal saline to remove excess tritiated leucine. After 
an eight minute spin at 350 g, the cell pellet was re­
suspended and given two washes with cold 3% acetic acid.
The cell pellet from the final spin was bleached with one
drop of hydrogen peroxide (30 vols) which was subsequently 
boiled off by heating at 84°C for 20-30 minutes. 0.6 ml 
NCS tissue solubiliser (Amersham/Searle Corporation) was 
then used to dissolve the cell pellet, and 10 mis scintil­
lation fluid added. The scintillation fluid used was a 
mixture of PPO (91%) and dimethyl POPOP (9%) at a con­
centration of 4 g/litre in toluene. This solution was then 
transferred to a scintillation vial and counted in a 
Packard Tri-carb liquid scintillation counter. Efficiencies
of 40-50% were usual. Responses to PHA were expressed as
% Ratio of Counts^min culture with PHA
Counts/min in unstimulated culture
Lymphocyte Transformation
A similar whole blood technique was used to investigate 
lymphocyte transformation in terms of tritiated thymidine 
uptake in response to PHA and various antigens. 1 nCi 
tritiated thymidine, specific activity 19 Ci/mmol 
(Radiochemicals, Amersham) was added to each lymphocyte 
culture 24 hours before harvesting. PHA cultures were 
harvested as described above, at 3 days to determine 
tritiated thymidine uptake. The antigen-stimulated 
cultures were harvested at 6 days.
CHAPTER 1
MEASUREMENT OF THYMUS-DERIVED LYMPHOCYTE FUNCTION 
IN PATIENTS WITH MALIGNANT BRAIN TUMOUR
Introduction 
There is compelling evidence that an increased 
incidence of malignant disease is found in patients with 
impaired cell-mediated immunity. This occurs whether the 
cell-mediated immune deficiency is congenital (Gatti and 
Good, 1971) or due to prolonged immunosuppressive therapy 
(Penn, Halgrimson and Starzl, 1971; Liebowitz and Schwartz, 
1971). Lymphomas and epithelial tumours have been reported 
most frequently, and in renal transplant patients in whom 
delayed hypersensitivity responses have been depressed, 
an unexpectedly increased number of cerebral lymphomas 
has occurred (Schneck and Penn, 1971; McCracken, 1973).
In patients with immune deficiency who develop 
tumours, there is some evidence that restoration of the 
immunity may abort the tumour (Valentine and Lawrence, 
1971). Similarly, in syngeneic animals grafted with 
malignant tumours, suppression or restoration of their 
cell-mediated immunity may cause enhancement or regression 
of the tumour (Balner and Dersjant, 1969; Denlinger, 
Swenberg, Koestner and Wechster, 1973; Arnstein, Taylor, 
Nelson-Rees, Huebner and Lennette, 1974).
Lymphocyte function has been shown to be defective 
in patients with cancer, as measured in vivo by impairment 
of cutaneous reactivity to common antigens (Solowey and 
Rapaport, 1965; Hughes and MacKay, 1965), delayed homo­
graft rejection (Brunschwig, Southam and Levin, 1965), 
impaired ability to become sensitised to dinitrofluoro-
benzene (DNFB) (Levin, McDonough, Miller and Southam, 1964), 
or to dinitrochlorobenzene (DNCB) (Eilber and Morton, 1970; 
Catalona, Taylor, Rabson and Chretien, 1972). In vitro 
tests of peripheral blood lymphocytes from these patients 
have also revealed a defect in T-cell function, namely, 
abnormally low responses to phytohaemagglutinin (Gatti, 
Garrioch and Good, 1970; Whittaker, Rees and Clark, 1971).
It was decided therefore to study a large group of 
patients with brain tumours, and to compare their responses 
to PHA to those of patients with other neurological diseases 
and normal healthy controls. A technique was also set up 
to test for a serum blocking factor in these patients, as 
previous workers have suggested that the immune defect 
found in patients with primary intracranial tumours might 
be due to a serum factor causing suppression of lymphocyte 
blast transformation (Brooks, Netsky, Normansell and 
Horwitz, 1972).
Methods
Patients
In this study the patients with benign or malignant 
brain tumours were all in good general health, apart 
from their neurological symptoms. They had no evidence 
of weight loss, anaemia or electrolyte disturbances. At 
the time of study, no operations (apart from biopsy) had 
been undertaken and no treatment had started.
Group A - 28 patients with malignant glioma in whom the 
diagnosis had been confirmed histologically.
There were 16 males and 12 females whose ages 
ranged from 16 to 71 years, with a mean age of 53.
Group B - 11 patients with disseminated carcinomatosis;
9 males and 2 females, whose ages ranged from 
31 to 70 years with a mean age of 63.
Group C - 9 patients with meningioma; 4 males and 5 
females aged 30 to 54 with a mean age of 
42 years.
Group D - 20 patients with various chronic neurological
diseases including cerebrovascular accident (3), 
intracranial hypertension (3), motor neurone 
disease (6), myasthenia gravis (6) and multiple 
sclerosis (2). There were 9 males and 11 
females whose ages ranged from 18 to 66 with a 
mean age of 49 years.
Group E - 21 normal controls consisting of medical and 
nursing personnel (8), patients with inter- 
vertebral disc lesions (10) and patients with 
migraine (3). There were 10 males and 11 
females whose ages ranged from 25 to 56 with a 
mean age of 38 years.
None of the patients studied were receiving steroids or 
immunosuppressive therapy at the time of the tests.
Cutaneous Reactivity
All subjects in groups A-E were skin tested as 
described in METHODS. Intradermal injections were per­
formed by Dr. M. Gunar.
Peripheral Lymphocyte Protein Synthesis
Carried out as described in METHODS.
Tests for a serum blocking factor using the assay
of peripheral blood lymphocyte protein synthesis
(a) Healthy donor lymphocytes and test serum:
60 mis of venous blood from healthy donors was 
collected as previously described. The cells obtained 
from each sample were washed x3 in tissue culture fluid 
RPMI 1640 and a lymphocyte count was done. The cell 
suspension was then divided into four aliquots and tissue 
culture medium added to each to give a final concentration
g
of 1 x 10 lymphocytes per 3 mis.
The medium was supplemented with one of the following:- 
(i) 10% autologous serum.
(ii) 10% foetal calf serum.
(iii) 10% serum from patients with glioma.
(iv) 10% serum pooled from patients with chronic 
neurological diseases.
The cells were then cultured for 48 hours at 37°C. 
Following this tritiated leucine was added and the material 
divided into 3 ml aliquots. Protein synthesis on stim­
ulation by various concentrations of PHA was then measured 
as described over the next 22 hours.
(b) Repeated washing of lymphocytes from patients with 
glioma to remove putative serum blocking factor: 
Lymphocytes from six patients with malignant glioma
were taken and the cells from each individual patient were 
washed carefully x3 in large volumes of RPMI 1640. They 
were then resuspended in tissue culture fluid supplemented 
with autologous or foetal calf serum, and protein synthesis 
was measured over 22 hours as described.
Results
Cutaneous Reactivity
All normal controls (Group E) showed a positive skin 
response of greater than 1 cm to SK/SD and Candida, and 
56% of the controls had a positive response to tuberculin 
(Table I). These results are in marked contrast to the 
poor responses in patients with glioma or in those with 
generalised carcinomatosis. Patients with benign tumours 
and patients with other neurological diseases showed no 
significant difference to healthy controls. Significance 
was calculated using Chi squared distribution.
Lymphocyte Function In Vitro
Figure 4 and Table II show graphically the response 
to lymphocytes in vitro from all five groups of patients. 
There is highly significant (as measured by Student's 
t-test) depression of lymphocyte protein synthesis in 
patients with glioma and carcinomatosis. Depressed 
lymphocyte responses to a much lesser extent were found 
in two other groups, i.e. patients with meningioma, and, 
as expected (Simpson, Behan and Dick, 1976; Behan, Dick 
and Durward, 1977), those with immune disorders in the 
control group. This is also seen in a scatter diagram 
(Fig. 5) of stimulation ratio of patients and control 
subjects at 8.33 ng/ml concentration of PHA.
Tests for a Serum Blocking Factor
No evidence of serum blocking factors was found.
Cell cultures from healthy donors showed no difference in 
their responses to varying concentrations of PHA, whether 
the cells were grown in autologous serum, foetal calf
TABLE I
CUTANEOUS REACTIVITY TO SK/SD, PPD AND CANDIDA
Clinical State
No. in
Percenl
greatei
tage showing response 
r than 1 cm diameter
Group
SK/SD* PPD** CANDIDA+
Glioma
A 28
18.5 11.1 18.5
P value .001 .005 .001
Carcinomatosis
B 11
18 45.5 36
P value .0001 NS .001
Meningioma
C 9
100 44.9 100
P value NS NS NS
Chronic neurological 
P diseases 20
80 55 80
P value NS NS NS
g Normal healthy 
controls
21 100 56 100
*SK/SD - 5 units/O.l ml
**PPD - 10 units/O.l ml
+CANDIDA - 0.5%
Fig. 4 shows graphically the response of lymphocytes 
in vitro from all five groups of patients. 
There is a highly significant (P < 0,00001) 
depression of lymphocyte protein synthesis in 
patients with glioma and carcinomatosis.
Patient
Group
Mean Tritium 
uptake in
10^ cpm*
Standard
Deviation
3m  10 cpm*
A 5.73 1.48
B 6.06 0.54
C 6.02 0.91
D 5.76 1.05
£ 5.78 2.49
* cpm - counts per minute
LYMPHOCYTE PROTEIN SYNTHESIS IN PATIENTS WITH
GLIOMA, MESTASTASES, MENINGIOMAS, CHRONIC NEUROLOGICAL * Controls (E)
GHoma Patients (A> 
Metastases (B) 
Meningiomas (C) 
Chronic Neurological 
Diseases(D)
DISEASES, AND - NORMAL HEALTHY CONTROLS.
300-
200-
100
80-
PHA Concentration (^ jg/ml)
TABLE II
LYMPHOCYTE RESPONSES IN PATIENTS WITH GLIOMA, CARCINOMATOSIS, 
MENINGIOMAS, CHRONIC NEUROLOGICAL DISEASES,
AND IN NORMAL HEALTHY CONTROLS
Patient
group
Stimulation indices (S.I.) at varying 
concentrations of PHA (ug/ml).
8.33 2.08 1.04 0.26 0.065
Mean 1.43 1.50 1.39 1.20 _
A s. d. 0.12 0.12 0.11 0.09 -
P. C 0.00001 <0.00001 <0.00001 <0.00001 -
Mean 0.09 1.00 0.98 0.95 -
B s.d. 0.11 0.07 0.05 0.02 -
P. <0.00001 <0.00001 <0.00001 <0.00001 -
Mean 1.80 1.70 1.71 1.32 -
C s.d. 0.16 0.11 0.09 0.07 -
P. <0.00001 <0.00001 <0.00001 <0.00001 -
Mean 1.79 1.82 1.72 1.41 1.07
D s. d. 0.24 0.19 0.22 0.18 0.12
P. <0.00001 <0.00001 <0.00001 0.006 0.187
Mean 2.47 2.33 2.11 1.61 1.03
E
s.d. 0.31 0.38 0.40 0.34 0.10
s.d. — standard deviation
P. = value of probability when compared 
with control group (E).
Scatter diagram of stimulation ratios of patients 
and controls to stimulation by PHA at a con­
centration of 8.33 jig/ml.
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serum, serum from patients with other neurological dis­
orders, or serum from patients with glioma (Fig. 6 and 
Table III). Similarly, lymphocytes from patients with 
malignant brain tumour revealed the same depression of 
protein synthesis whether they were washed repeatedly in 
tissue culture fluid and grown in RPMI to which foetal 
calf serum had been added, or whether they were washed 
and grown in the presence of autologous serum (Fig. 7 
and Table IV).
Discussion
These studies show that patients with primary 
malignant intracranial tumours have impaired lymphocyte 
function, as measured in vivo by cutaneous reactivity to 
recall antigens, and in vitro by depressed lymphocyte 
protein synthesis. At the time of study these patients 
were otherwise healthy with no evidence of infection, 
weight loss, haematological or hepatic dysfunction. The 
significance of the anergy found is unknown and whether 
or not it contributes to the induction of the tumour or 
modifies its rate of growth remains to be determined.
There is good evidence from clinical observations and 
from animal experiments that the immune response of the 
host may influence tumour growth in other systems of the 
body (Valentine and Lawrence, 1971). Patients with 
naturally occurring, congenital or acquired defects of 
cell-mediated immunity have an increased incidence of 
tumour (Gatti and Good, 1970) and indeed lymphomas are 
unexpectedly frequent in the central nervous system of 
patients receiving immunosuppressive therapy for renal 
transplantation (Schneck and Penn, 1971). These tumours
TABLE III
CELLULAR RESPONSES OF WASHED HEALTHY LYMPHOCYTES IN 
SERUM OF PATIENTS WITH GLIOMA AND OTHER DISEASES
Stimulation indices (S.I.) at varying 
concentrations of PHA (ug/ml).
33.33 8.33 2.08 1.04 0.26 0.065 0.016
Autologous
n 9 23 23 23 23 23 9
Mean 2.10 2.72 2.83 2.85 2.24 1.75 1.08
s.d. 0.44 0.47 0.66 0.64 0.36 0.44 0.17
P. - - - - - - -
Foetal calf
n 7 19 19 19 19 19 7
Mean 1.92 2.15 2.74 2.73 2.14 1.45 1.15
P . 0.39 0.02 0.73 0.67 0.6 0.08 0.42
Pooled serum 
from patients 
with chronic 
neurological 
diseases
n 7 7 7 7 7 7 7
Mean 2.11 2.61 2.67 2.47 2.1 1.63 1.13
s.d. 0.3 0.42 0.54 0.61 0.52 0.4 0.27
P. 0.91 0.63 0.61 0.25 0.56 0.58 0.68
Pooled serum 
from patients 
with glioma
n 18 18 18 18 18 18 18
Mean 2.07 2.41 2.46 2.45 1.91 1.43 1.05
s.d. 0.45 0.53 0.4 0.51 0.39 0.26 0.21
P. 0.85 0.14 0.15 0.12 0.04 0.07 0.7
n = number of tests done
s.d.= standard deviation
P. = value of probability when compared 
with autologous serum.
Fig. 6 shows cellular responses of washed healthy 
lymphocytes cultured in sera from patients 
with glioma and other diseases.
Fig. 7 shows cellular responses of lymphocytes from 
patients with glioma. These cells were 
cultured in either foetal calf or autologous 
serum, following repeated washing.
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STIMULATION INDICES OF WASHED HEALTHY LYMPHOCYTES IN SERUM 
OF PATIENTS WITH GLIOMA & OTHER DISEASES
4 Glioma Sera 
• Autologous
* FCS
■ Other Diseases400-
|  300-cutr
200-
100-
100100100-1001
Concentration of PHA(jjg/ml)
Cellular Responses in Autologous & Foetal Calf Sera
200-I
•Cells in Autologous Serum  (6) 
* Cells -  F.C.S. (6)
150-
100
Concentration of PHACjjgyVnl)
TABLE IV
CELLULAR RESPONSES IN AUTOLOGOUS AND FOETAL CALF SERA
Patient
Serum
supplement
Stimulation indices (S.I.) at vary­
ing concentrations of PHA (ug/ml).
8.33 , 2.08 1.04 0.26 0.065
1 Autologous 
Foetal calf
1.23
1.27
1.18
1.34
1.18
1.34
1.05
1.24
0.85
1.03
2 Autologous 
Foetal calf
1.55
1.37
1.49
1.62
1.47
1.64
1.42
1.43
1.10
1.22
3 Autologous 
Foetal calf
1.41
1.09
1.46
1.26
1.56
1.27
1.24
1.16
1.09
1.07
4 Autologous 
Foetal calf
1.16
1.21
1.43
1.24
1.30
1.22
1.27
1.32
0.94
1.00
5 Autologous 
Foetal calf
1.21
1.23
1.05
1.12
0.85
1.21
0.94
1.00
0.98
0.96
6 Autologous 
Foetal calf
1.36
1.65
1.33
1.41
1.13
1.30
1.17
1.00
1.00
0.78
Autologous sera 
Mean S.I.
S.D.
1.32
0.15
1.32
0.17
1.25
0.26
1.18
0.17
0.99
0.09
Foetal calf serum 
Mean S.I. 
s.d,
CP.
1.30
0.19
0.82
1.33
0.17
0.88
1.33
0.16
0.54
1.19
0.17
0.88
1.01
0.14
0.77)
s.d. = standard deviation 
P. = probability value.
p. 26 line 13 should read:- "responses of lymphocytes 
from patients with glioma to Concanavelin A ...."
may diminish in size or disappear on withdrawal of immuno­
suppressive treatment (Wilson, Hager, Hampers, Corson,
Merrill and Murray, 1968; Zukosi, Killen, Ginn, Matter,
Lucas and Seigler, 1970; Schneck and Penn, 1970),
Several studies have previously suggested that immuno- 
competence may be altered in patients with glioma, e.g. there 
is a reduction in the number of circulating lymphocytes and 
skin reactions to PPD, SK/SD, mumps, Candida, and tri­
chophyton antigens are impaired, as is the ability of 
these patients to become sensitised to DNCB (Brooks et al, 
1972; Mahaley, 1975). Young, Sakalas and Kaplan (1976) 
confirmed the above findings and also noted reduced in vitro 
responses of patients with glioma to Concanavalin A. They 
found that the abnormalities were confirmed to patients 
with astrocytomas of Grade III and IV, in contrast to the 
results of the previous workers. In a separate study,
Mahaley, Brooks, Roszman, Bigner, Dudka and Richardson 
(1977) confirmed that the skin reactions to foreign anti­
gens were diminished to a much greater extent in patients 
with the more malignant tumours.
In contrast to these reports of generalised anergy in 
patients with glioma, the results of other studies suggest 
that the body may mount an immunological attack on these 
tumours. For instance, Kumar and Taylor (1973) demonstrated 
cytotoxic lymphocytic activity against astrocytomas and 
similar results, with cytotoxic effects to a common anti­
gen from astrocytomas, were reported by Levy, Mahaley and 
Day (1972). The importance of these two studies lies also 
in the fact that both groups detected a serum blocking 
factor in the patients which impaired the ability of
immunocompetent cells to kill tumour cells in vitro.
The nature of the factor or factors was not identified.
Brooks et al (1972) demonstrated a serum factor 
capable of depressing in vitro lymphocyte transformation 
and stated that the amount of the factor present could 
be correlated with the degree of anergy. The blastogenic 
responses of lymphocytes from both patients and normal 
controls were diminished by the serum factor; and lympho­
cytes from patients which had shown impaired responses 
were found to be capable of normal in vitro reactions 
after repeated washings. We have been unable to confirm 
these observations in this study. The difference, however, 
may be more apparent than real, in that we took lymphocyte 
protein synthesis measured over 22 hours as an indication 
of lymphocyte function, whereas Brooks et al (1972) 
measured DNA synthesis over 2 hours in lymphocytes cultured 
with mitogens or antigens for 4-6 days. Our technique, 
therefore, may not have been sensitive enough to measure 
this blocking factor.
Inhibitors of lymphocyte function have been described 
in the serum of patients with cancers outside the central 
nervous system (Silk, 1967; Sample, Gertner and Chretien,
1971) and specific blocking or tumour-enhancing activity 
has also been demonstrated in the serum of both humans and 
animals with neoplasms (Hellstrom and Hellstrom, 1970). 
Brooks et al (1972) thought that the blocking factor in 
the serum of patients with glioma corresponded to the 
immunoglobulin fraction and was IgG but others have dis­
agreed (Young et al, 1976). In a detailed study of 
patients with solid tissue neoplasms Glasgow, Nimberg,
Menzoian, Saporoschetz, Cooperband, Schmid and Mannick 
(1974) found a circulating immunosuppressive serum com­
ponent in the first peak, Fraction 1, after ion-exchange 
chromatography of the serum. They had previously shown 
that there was an immunoregulatory fraction in the alpha- 
globulin of normal human serum (Cooperband, Badger, Davis, 
Schmid and Mannick, 1972). They concluded that the pep­
tide fraction isolated was different to the blocking 
factor found in the serum of cancer patients by Hellstrom 
and Hellstrom (1970) or by Baldwin, Price and Robbins 
(1973).
Similar blocking factors have also been reported in 
animals (Kamrin, 1959; Mowbray, 1963), and in other con­
ditions, such as in patients undergoing rejection of renal 
transplants (Riggio, Schwartz, Bull, Stenzel and Rubin, 
1969), patients with infectious diseases (Pearmain et al, 
1963) or in patients with presumed autoimmune disorders 
(Jensen, 1968). It is clear, therefore, that the immuno­
suppressive serum factors detected by different workers 
may not be identical to one another and controversy cer­
tainly exists, not only as to their mode of action, 
identification and precise nature, but even as to their 
existence.
We have demonstrated a general anergy in patients 
with glioma, but there are several reports indicating 
that patients with glioma may become specifically 
sensitised to the tumour. These comprise tissue culture 
studies (Eggers, 1972), skin-testing (Bloom, Carstairs, 
Crompton and McKissock, 1960; Febvre, Manoury, Constans 
and Trouillas, 1972; Grace, Perese, Metzgar, Sasabe and
Holdridge, 1961; Trouillas, 1972) and cytotoxicity experi­
ments (Ciembroniewicz and Kolar, 1969; Jagarlamooday, Aust, 
Tew and McKhann, 1971; Koprowski and Fernandes, 1962;
Levy et al, 1972; Mitts and Walker, 1965; Wahlstrom, Saksela 
and Troupp, 1973).
In addition, histological evidence may suggest an immune 
response: lymphocyte infiltration of a wide variety of 
malignant tumours has been observed (Tsakraklides, 
Anastassiades and Kersey, 1973; Pratt, Brynes, Vardiman 
and Coppleson, 1975), and a correlation has been demonstrated 
between the clinical course of these patients and the immuno­
logical responses to the tumour. Indeed, in patients with 
breast cancer, the degree of lymphocyte infiltration has 
been stated to give as good an index of prognosis as the 
histological grade of dedifferentiation (Hamblin, 1968).
Some workers have suggested that a similar state of affairs 
may exist for the degree of lymphocyte infiltration around 
brain tumours and survival (Ridley and Cavanagh, 1971; 
di Lorenzo, Palma and Nicole, 1977; Brooks, Markesbery,
Gupta and Roszman, 1978). Observation of transplanted 
tumours in animals has provided further evidence that 
aggressive lymphocytes may be responsible for tumour re­
gression, and that the rate of elimination of the grafted 
tumours is related to the degree of the cell-mediated immune 
response (Scheinberg, Edelman and Levy, 1964; Scheinberg,
Levy and Edelman, 1965; Scheinberg and Taylor, 1968).
This study has confirmed that otherwise healthy 
patients with malignant brain tumours have significant 
depression of lymphocyte function. There is compelling 
evidence that a similar type of anergy can influence tumour
growth in other systems and, in regard to the brain, a 
preliminary report has suggested that therapy with auto­
logous lymphocytes may modify the rate of growth of 
glioblastoma multiforme (Young, Kaplan and Regelson, 1977). 
Further study to clarify the factors operative in the 
disordered immunity shown by patients with glioma is 
clearly warranted.
CHAPTER 2 
THE EFFECT OF P-BLOCKERS ON 
LYMPHOCYTES IN VITRO
Int roduct ion 
Various adverse reactions have been reported in 
patients undergoing treatment with practolol, a beta- 
blocking drug used to control angina and hypertension.
These include exfoliate dermatitis (Rowland and Stevenson,
1972); eczematous, lichenoid, psoriasiform skin rashes 
(Felix, Ive and Dahl, 1974); a syndrome resembling systemic 
lupus erythematosis (Raftery and Denman, 1973); nephrotic 
syndrome (Farr, Wingate and Shaw, 1975); fibrinous peri­
tonitis (Brown, Baddeley, Read, Davies and McGarry, 1974; 
Hensen, Rhemrev and Kapteyn, 1975; Windsor, Kurrein and 
Dyer, 1975); and the oculomucocutaneous syndrome (Wright, 
1975).
The discovery in patients with ocular damage of 
high titres of antinuclear antibodies and antibodies 
binding to the intercellular region of xenogeneic epi­
thelial tissues (Amos, Brigden and McKerron, 1975) and 
the demonstration of the deposition of IgG, IgM and C3 
at the dermoepidermal junction and circulating antinuclear 
antibodies in several patients with skin reactions (Felix 
et al, 1974) suggested that an abnormal immune response 
might be involved. Further, the possibility of a primary 
immunological mechanism for the oculomucocutaneous syndrome 
was suggested when a survey of reports of patients carried 
out by ICI found that adverse reactions were not related 
to dosage and, therefore, were unlikely to be pharmaco­
logically or toxicologically induced.
It was decided therefore to measure the protein 
synthesis, in vitro, of peripheral blood lymphocytes of 
patients taking practolol, and who had developed adverse 
reactions. The results are compared with those obtained 
in a group of patients in whom no adverse effects had 
developed and in a control group of normal healthy 
individuals, who had never taken practolol. Lymphocyte 
blast transformation was also measured by culturing cells 
from patients with adverse symptoms, in the presence of 
PHA, and the drug itself, and comparing results to those 
of normal lymphocytes cultured under similar conditions.
In addition, further studies were carried out to 
test the effect of several beta-blocking drugs on normal 
peripheral blood lymphocytes in vitro.
Methods
Patients
The following groups were studies:- 
Group A - 15 patients in whom either cutaneous lesions or 
a combination of cutaneous and ocular lesions developed 
whilst on practolol. There were 4 females and 11 males 
with an average age of 61 years (range 35-75 years).
The average dose of practolol was 1200 mg/day (range 200- 
2400 mg/day) and the average duration of practolol treatment 
before the first symptoms of the oculomucocutaneous 
syndrome appeared was 29 months (range 9 to 51 months).
At the time of study, 3 patients were still taking practolol, 
1 had been off for 6 days, and the remainder had stopped 
taking practolol for 1 to 36 months. However, the rash 
persisted in 4 patients and 9 still had ocular symptoms 
and signs. In the 2 remaining patients the rash had
resolved. Most patients had been transferred to an 
alternative beta-blocker together with a thiazide diuretic 
Group B - 3 patients, 1 male and 2 females who had 
sclerosing peritonitis confirmed by laparotomy. Practolol 
(200-300 mg/day) had been used for 18 to 36 months before 
the onset of abdominal symptoms. In 2 of the patients 
ocular lesions were said to have developed as well as 
the sclerosing peritonitis, and the third had had an 
exfoliative dermatitis. All 3 patients had stopped taking 
practolol for up to 18 months before the start of the 
present study.
Group C - 6 male patients who had been receiving 400 mg/ 
day of practolol for about 2 years for the treatment of 
ischaemic heart disease, and all were still on practolol 
at investigation.
Group D - 35 healthy controls, 20 males and 15 females 
whose mean age was 38 years (range 30-56 years), made 
up of medical and nursing personnel.
(This study was carried out before the withdrawal of 
practolol (•Eraldin*) tablets from general use.)
Drugs
Drugs tested in vitro were
(a) Practolol (Imperial Chemical Industries Ltd.,
Alderley Park, Macclesfield).
(b) A metabolite of practolol (ICI, Macclesfield)
(Fig. 8).
(c) Propranolol (ICI, Macclesfield) (Fig. 9).
(d) Metoprolol tartrate ( 'Betaloc' , Astra Chemicals Ltd. 
Watford).
Fig- 8
Fig. 9
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Propranolol ( I.C.I)
(e) Oxprenolol hydrochloride ('Trasicor', Ciba Laboratories,
Horsham)•
Protein Synthesis by Peripheral Blood Lymphocytes
Carried out as described in METHODS.
Lymphocyte Transformation
Carried out as described in METHODS. Lymphocytes 
were cultured in the presence of PHA at a concentration 
of 8.7 |ig/ml, and also in the presence of practolol, and 
a metabolite of practolol both at a final concentration 
of 50 iig/ml. Candida albicans antigen was also used at 
a concentration of 0.1 ml of the standard solution 
(Bencard) in each 3 ml culture.
To test the effect of beta-blocking drugs, in vitro, on 
normal healthy lymphocytes, by measurement of protein 
synthesis
Venous blood from healthy donors was collected as 
previously described. A cell count was done, and the 
cells prepared as for peripheral lymphocyte protein 
synthesis. Before the addition of the tritiated leucine, 
however, a measured amount of each of the drugs was 
added to each bottle containing cells, and these were 
then incubated at 37°C for 48 hours. Five different 
drugs were used, each at a final concentration of 10, 50,
100 and 250 ng/ml. Tritiated leucine was then added, the 
material divided into 3 ml aliquots and protein synthesis 
on stimulation by two concentrations of PHA (8.33 and 2.04 
jig/ml) measured over the next 22 hours, as described 
previously.
This technique was further modified by extensively 
washing the cultured cells after 48 hours with tissue 
culture fluid then comparing the results of their protein 
synthesis with those of cells cultured in a similar 
fashion, but not washed before the addition of PHA.
Results
Protein Synthesis in Response to PHA
The overall response of lymphocyte protein synthesis 
was significantly less in the patients with the oculo­
mucocutaneous syndrome (Group A) than in the controls 
(Group D), as shown in Fig. 10. Similar results (Fig. 11) 
were obtained in the 3 patients (Group B) with sclerosing 
peritonitis. The results of lymphocyte testing in 
patients who had been on practolol for 2 years (Group C) 
were also abnormal (Fig. 12). At the optimum concentration 
of PHA there was a significant (P = < 0.01) between the 
response of their lymphocytes and that of control 
lymphocytes•
Lymphocyte Transformation Tests
The lymphocyte PHA responses after culture for 3 
days, as measured by tritiated thymidine uptake, were 
depressed in the patients with eye and skin manifestations 
of the oculomucocutaneous syndrome (Table V). There was 
no significant response to practolol or one of its possible 
metabolites in any of the patients or controls.
Effect of Beta-blocking Drugs In Vitro
Incubation of normal healthy lymphocytes with 
practolol had no effect on the response to PHA at either
Ficr. 10 Protein synthesis by PHA-stimulated lymphocytes 
from patients with the oculomucocutaneous 
syndrome (Group A) compared with normal controls 
(Group D).
Fig. 11 Protein synthesis by PHA-stimulated lymphocytes 
from patients with sclerosing peritonitis 
(Group B) compared with normal controls 
(Group D)•
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Fig. 12 Protein synthesis by PHA-stimulated lymphocytes 
from patients on long-term practolol therapy 
without lesions (Group C) compared with normal 
controls (Group D).
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TABLE V
LYMPHOCTYE BLAST TRANSFORMATION IN PATIENTS 
FROM GROUP A WITH OCULOMUCOCUTANEOUS SYNDROME 
COMPARED WITH NORMAL HEALTHY CONTROLS.
STIMULATION RATIO (%)
GROUP
PHA*
C8ug/ml)
PRACTOLOL**
C50ug/ml)
METABOLITE**
C50ug/ml) CANDIDA**
Normal Healthy 
Controls ■x 21.15 1.06 1.26 1.04
(n = 5) s.d. + 10.58 0.06 0.17 0.27
GROUP A X 9.88 1.05 1.37 0.96
(n = 15) s. d. 8.59 0.07 0.26 0.15
P. 0.02 NS NS NS
* 3 day culture
** 6 day culture 
P calculated using Students t test.
p. 36 line 14 should read:- "....there was no 
difference between the responses...."
36
concentration (Fig. 13). Very little effect was also 
seen after culture with the metabolite or with Betaloe 
which showed only slight impairment of the lymphocyte 
response at the higher drug concentrations (Figs. 14 and 
15). Trasicor had a more pronounced effect on the 
reactivity of the PHA stimulated cells (Fig. 16) but the 
greatest depression of response was seen after cultures 
with propranolol (Fig. 17) where, at concentrations of 
50 ng/ml and over, comparisons to controls were highly 
significantly different with P < 0.00001.
Comparison of washed and unwashed cells was done 
on 3 sets of cells cultured with four concentrations of 
Trasicor. In both cultures with PHA at 8.33 and 2.04 
ng/ml there is no difference between the responses of 
washed and unwashed lymphocytes cultured alone, or in the 
presence of the drug at a concentration of 10 jxg/ml. At 
concentrations of Trasicor of 50, 100 and 250 ng/ml, 
however, washing of the cells before incubation with PHA 
increased the response seen (Table VI).
Discussion
Practolol therapy may be associated with various 
adverse reactions (British Medical Journal, 1975). 
Although all of the practolol reactors were not still on 
practolol when they became involved in this investigation, 
they did, however, continue to have symptoms and signs 
related to practolol toxicity. A survey of reports on 
patients with the oculomucocutaneous syndrome carried 
out at ICI indicates that the reaction is not related 
to dose, dosage regimen, or total cumulative amount of 
practolol received. Further, there appeared to be no
In vitro effect of practolol on normal 
PHA-stimulated lymphocytes.
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Fig, 14 Measurement of protein synthesis in normal 
PHA-stimulated lymphocytes incubated in the 
presence of a metabolite of practolol.
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Fig. 15 The effect of Betaloc in vitro on normal 
PHA-stimulated lymphocytes.
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PHA-stimulated lymphocytes.
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Fig, 17 P value at PHA concentration of 
8.33 jig/ml, drug concentration of 10 |ig/ml 
should read < 0.00001.
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TABLE VI
COMPARISON OF PHA STIMULATION RATIOS OF 
WASHED AND UNWASHED LYMPHOCYTES CULTURED IN 
THE PRESENCE OF TRASICOR
CONCENTRATION OF TRASICOR
PHA 8.33 ug/ml PHA 2.04 ug/ml
UNWASHED WASHED UNWASHED WASHED
Controls x 1.53 1.65 1.53 1.62
(n = 3) S,d* 0.17 0.29 0.12 0.31
P. NS NS
10 ug/ml x 1.54 1.59 1.57 1.45.
(n = 3) s,d* 0.34 0.25 0.18 0.27
P. NS NS
50 ug/ml x 1.40 1.61 1.45 1.77
(n = 3) s,d* 0.25 0.27 0.25 0.29
P. NS NS
100 ug/ml x 1.34 1.65 1.37 1.60
Cn = 3) S-d‘ 0.13 0.45
0.38 0.29
P. NS NS
250 ug/ml x 1.06 1.39 1.06 1.44
Cn = 3) S-d* 0.07 0.14 0.14 0.19
P. 0.02 0.04
causal relation with co-administered drugs, and there was 
no reason to believe that any of the other drugs that the 
patients were taking at the time of the investigation 
were likely to affect the immunological parameters being 
measured.
All of the patients who had reacted to practolol 
showed depressed cell-mediated immunity as demonstrated 
by the lowered in vitro responses of their peripheral 
blood lymphocytes to stimulation by PHA, both in a short 
term and also a three day culture. There was also 
evidence, however, of depressed lymphocyte function in 
those patients who had been on long term practolol therapy 
without the development of overt toxic reactions to the 
drug. It is not possible to say whether the depression 
of lymphocyte function is a precursor of the oculomuco- 
cutaneous reaction, as this syndrome did not later develop 
in any of those patients on long term practolol with 
impaired lymphocyte function.
Neither practolol itself nor one of its potential 
metabolites affected the transformation of lymphocytes 
derived from patients with oculomucocutaneous syndrome. 
This may have been due to the time of testing, since 
Houwerzijl and de Gast (1977) did sequential studies on 
two patients with a hypersensitivity reaction to 
carbamazepine, and found that during the reaction there 
was an impaired response with PHA and no transformation 
in the presence of carbamazepine, whereas some months 
the sensitivity reaction, a higher lymphocyte reactivity 
to PHA, and transformation with carbamazepine were found.
In a study of the sera from patients on practolol
p. 38 line 3 should read:- and rheumatoid"
with oculomucocutaneous syndrome, Behan, Behan, Zacharias 
and Nicholls (1976) showed the presence of various auto­
antibodies, especially antinuclear antibody, and rhumatoid 
factor. This may suggest an autoimmune disorder, however 
patients on long term practolol therapy with no adverse 
reactions also were found to possess various autoantibodies 
in their sera.
Certain beta-blockers were shown to depress the 
reaction of normal lymphocytes to PHA. This was especially 
true of propranolol and Trasicor. The reaction, however, 
was not irreversible, as washing the cells before culturing 
with PHA restored normal responses. In order to explain 
what is happening in this in vitro situation it is necessary 
to understand the role of adrenergic receptors.
Communication between neurones and end organs 
(e.g. muscles, glands) is primarily via transmission of 
chemical signals across juxtapositioned specialised cell 
surface regions which together constitute a synapse.
Studies using various methods (Daniels and Vogel, 1975) 
have revealed that the post synaptic membranes are packed 
with receptors, specific for each of the known neuro­
transmitters. Cholinergic synapses are found between 
post-ganglionic motor nerve fibres and skeletal striated 
muscle, and the neurotransmitter molecule is mainly 
acetylcholine. Sympathetic nerve post-ganglionic synapses 
with smooth muscles and glands are, in contrast, exclusively 
adrenergic, and transmission is mediated by norepinephrine. 
Although these transmitters are only produced by cells of 
'neural' origin, they can function either locally as 
adrenergic neurotransmitters, or systemically as adrenergic 
hormones.
The subdivision of adrenoreceptors into two broad 
categories a and p, was first suggested by Ahlquist 
(1948), and is now well established. These two receptors 
differ in physical or chemical properties in such a way 
as to distinguish their affinity for various sympatho­
mimetic amines. In general, the effect on a receptors 
is excitatory, and on p receptors inhibitory, but this 
is not an absolute rule. Sympathetic receptor cells may 
have a or P receptors on their surface, or both.
There is much less agreement, however, on the 
validity of the further subdivision of {3-adrenoreceptors 
into P^ and P  ^subgroups (Lands, Arnold, McAuliff, Ludufna 
and Brown, 1967), principally because there seem to be too 
many receptors which will not fit neatly into either group 
(Bristow, Sherrod and Green, 1970; Lefkowitz, 1975). 
Nevertheless it remains a clinically useful concept since 
it has been possible to develop relatively cardioselective 
(P^) adrenoreceptor antagonists such as practolol, and 
metaprolol, which may be used to treat angina or hyper­
tension, whereas selective (3 2 agonists such as salbutamol 
and terbutaline are being used in the treatment of 
bronchial asthma since they produce bronchodilation.
While looking for a model system to study adrenergic 
receptor function and malfunction in relation to disease, 
it was found that leucocytes possess both a and p adreno- 
receptors (Logsdon, Middelton and Coffey, 1972).
Assessment of the lymphocyte p-adrenoreceptor was done by 
Connolly and Greenacre (1977) who categorised it as P2 . 
They also showed that the lymphocyte padrenoreceptor is 
readily blocked by propranolol, but appears to be far less 
sensitive to the effect of practolol. It was also noted
that practolol is far more polar than propranolol, and 
in experiments using aqueous media, it will preferentially 
partition into the medium rather than into the lipid of 
the cell membrane, and this may hinder access to the 
receptors. For the lipid soluble propranolol the reverse 
will be the case, tending to exaggerate the already 
substantial difference in potency of the two drugs with 
respect to the (32 receptor.
It is assumed that neurotransmitters initiate 
responses on excitable neurones, or non-neural tissue by 
a purely cell surface action on receptors. This is 
supported by studies on reconstituted acetylcholine 
receptors in artificial membranes (Rang, 1973: Axelrod, 
1974). Greaves (1975) states that activation of the cell 
surface p-adrenergic receptor causes the enzyme adenyl 
cyclase to act as a catalyst in the formation of cyclic 
AMP from magnesium ATP. The important role that cyclic 
AMP plays in regulating cell proliferation and growth 
has already been discussed earlier in this work.
Thus we see there is a direct link between the 
P-adrenergic receptor on lymphocytes, and the process 
of protein synthesis by these cells. This would explain 
why propranolol should have such an adverse effect on 
normal lymphocytes in vitro when stimulated by PHA.
CHAPTER 3 
IN VITRO LYMPHOCYTE FUNCTION IN 
PATIENTS ON ANTICONVULSANTS
Introduction 
Several immunological abnormalities have been 
described in patients taking phenytoin (di-sodium 
phenylhydantoin), an anticonvulsant drug widely used 
in the treatment of epilepsy. These abnormalities have 
included depressed cellular and humoral immunity, and 
low serum immunoglobulin A (IgA) (Sorrell, Forbes, Burness 
and Rischbieth, 1971; Grob and Herold, 1972; Slavin,
Fenton, Laundy and Reynolds, 1974). In a detailed study 
cell-mediated immunity was measured in vivo by skin test­
ing with ubiquitous recall antigens, and in vitro by 
measurement of lymphocyte DNA and RNA synthesis, and was 
found to be depressed. Low IgA levels together with 
defective antibody production to Salmonella typhii and 
tetanus toxoid were also found (Sorrell and Forbes, 1975). 
It was subsequently suggested that epilepsy with con­
stitutional characteristics might predispose to low IgA 
and that low IgA only occurs when hydantoins are given 
(Fontana, Grob, Sauter and Joller, 1976). It was therefore 
decided to study a large group of patients on phenytoin 
and other anticonvulsants to determine their immunological 
responses, and to see if there was any correlation with 
their HLA histocompatability status.
Methods
Patients
Thirty one patients suffering from epilepsy were 
studied, whose ages ranged from 27 to 76 years, with a
mean age of 47 years. These patients were divided into 
four groups.
(i) 10 patients (7 males and 3 females) who were taking
phenytoin as part of their anticonvulsaint medication, 
and were shown to have constantly low serum IgA 
levels;
(ii) 10 patients (5 males and 5 females) who were taking 
phenytoin but had consistently normal serum IgA 
levels;
(iii) 10 patients (4 males and 6 females) who were on 
anticonvulsant drugs other than phenytoin 
(including phenobarbitone, primidone, carbamazepine, 
sodium valproate and ethotoin), and had normal 
serum IgA levels;
(iv) 1 patient (female) who was on no drugs.
The duration of treatment was greater than 10 years in 
all patients.
Serum IgA levels had been determined by Dr. R. Shakir, 
Institute of Neurological Sciences, Glasgow, using radial 
immunodiffusion, and the Technicon AIP system. The 100% 
mean normal adult value (MNA) for IgA was 248 mg/dl, and 
the normal range was 50-175% MNA (Fahey and McKelvey,
1965). Any result, therefore, under 50% MNA was taken 
to indicate a low serum IgA level.
Peripheral Blood Lymphocyte Protein Synthesis
This was carried out as described in METHODS.
Results
A highly significant depression of protein synthesis 
was found in all 30 patients taking anticonvulsant drugs, 
irrespective of their IgA levels, or which drug was being
given. They all showed significant depression when 
compared to the controls, at PHA concentrations 1, 2 
and 8 ug/ml (Figs. 18-20). The dose response curve of 
the one patient on no drugs was in the range of the 
normal controls (Fig. 21).
Discussion
There is good evidence that immunological abnormalities 
are found in patients taking anticonvulsants. Shakir (1977) 
demonstrated that phenytoin affects the IgA producing 
plasma cells confirming reports of depressed IgA levels 
in both serum and saliva of epileptic patients by Aarli 
(1976a; 1977). Impairment of T-cell function as measured 
in vivo by lack of cutaneous reactivity to ubiquitous 
recall antigens, and in vitro by depressed lymphocyte DNA 
and RNA synthesis, has also been shown in patients on 
phenytoin therapy (Sorrell and Forbes, 1975; Masi,
Paolucci, Perocco and Franceschi, 1976). The presence 
of immunological defects, however, was independent of the 
dosage of drug, its serum concentration, the duration of 
therapy and the sex of the subject (Sorrell and Forbes,
1975; Shakir, Behan, Dick and Lambie, 1978).
Conspicuous impairment of T-cell function, as 
measured by lymphocyte protein synthesis was seen in all 
patients on anticonvulsants examined in this study. The 
only normal response was seen in one patient whose 
epilepsy was not yet being treated with drugs. Clearly 
more patients of this type have to be studied before any 
conclusions can be drawn but this finding could tie in 
with work done by Aarli (1976b), in which normal levels 
of IgA in untreated patients began to fall during the
Fig. 18 Lymphocyte protein synthesis in epileptic 
patients on phenytoin with low IgA levels.
Fig. 19 Lymphocyte protein synthesis in epileptic
patients on phenytoin with normal IgA levels.
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Fig. 20 Lymphocyte protein synthesis in epileptic 
patients on other anticonvulsants with 
normal IgA levels.
Fig. 21 Lymphocyte protein synthesis in one 
epileptic patient on no drugs.
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phenytoin therapy.
Sorrell and Forbes (1975) studied the effect of 
phenytoin on normal lymphocytes in culture, and showed 
a significant depression of DNA synthesis in both PHA- 
stimulated, and non-stimulated cells. This immunosuppression 
was shown to be the result of a direct effect of phenytoin 
on the metabolism of lymphoid, and in particular thymus 
derived, cells. Carbamazepine, another anticonvulsant 
drug, was shown to have a similar but less potent effect. 
Bluming, Homer and Khiroya (1976) found that phenytoin in 
concentrations approximating therapeutic blood levels, 
also inhibited mixed lymphocyte culture proliferation.
One possible explanation for these findings is that all 
patients on anticonvulsants have been shown to have a low 
serum folate level (Shakir, 1977), and this is known to 
affect cellular nucleic acid synthesis (Norris and Pratt, 
1974), and thus the extent of lymphocyte reactivity.
Impaired T-cell function is possibly also involved 
in the reduced IgA levels seen in the sera of patients on 
anticonvulsants, since IgA function has been shown to be 
related to intact thymic function (Lancet, 1975). Bankhurst 
and Warner (1972) showed that congenitally athymic nude 
mice have IgA deficiency although they may have many IgA 
bearing B-lymphocytes. This is similar to patients with 
IgA deficiency secondary to phenytoin therapy (Sorrell and 
Forbes, 1975), who also have normal numbers of IgA bearing 
B-lymphocytes but low serum IgA levels. In animal experi­
ments impaired immune responses, atrophy of thymic and 
lymphoid tissue and increased incidence of lymphoid tumour 
were produced by chronic phenytoin ingestion (Kruger and
p. 45 line 8 should read;- “an increased frequency 
of HLA-A2....“
Harris, 1972).
The mechanisms involved in producing these immune 
deficiencies are unknown, but it has been suggested by 
Fontana et al (1976) that a genetic factor may be operative. 
In a study of epileptic patients with low serum IgA, they 
detected a trend for the histocompatibility antigen HLA-A2. 
This was also demonstrated by Shakir et al (1978) who found 
a frequency of HLA-A2 in those patients taking phenytoin, 
with low IgA levels, as compared to those taking phenytoin, 
but with normal serum IgA. These findings strongly support 
the hypothesis that phenytoin causes selective IgA 
deficiency in genetically pre-disposed patients, whereas 
T-lymphocyte malfunction is a direct result of any anti­
convulsant therapy.
CONCLUSIONS
The method of in vitro protein synthesis has been 
demonstrated to be a sensitive technique for measuring 
thymus-derived (T-cell) lymphocyte function. The technique 
when applied to patients (a) with brain tumours, (b) on 
{3-blocking drugs, and (c) on anticonvulsants, demonstrated 
depressed lymphocyte activity.
The results obtained in patients with brain tumours 
and in patients with other malignancies are supported by 
both clinical evidence and other laboratory findings of 
impaired immunity. Such findings may have significance 
for therapy.
Lymphocytes have receptors on their surface for a 
large variety of substances. Impairment of the lympho­
cyte response in patients taking practolol, and results of 
in vitro studies involving cultures of normal lymphocytes 
with various |3-blocking drugs shows that one of these is 
a P-adrenergic receptor. The blocking of this receptor 
caused depressed lymphocyte protein synthesis in the 
presence of PHA.
Finally the technique helped to elucidate the impair­
ment of immune function in epileptic patients on 
anticonvulsants. The depression in T-cell activity was 
secondary to genetic and environmental factors and gave 
rise, by lack of T-cell co-operation to reduced IgA levels 
in some patients.
The technique of in vitro protein synthesis is thus a 
useful laboratory test which is reproducible and sensitive, 
and can be applied to elucidate a large number of con­
ditions in which changes in T-lymphocyte function may be 
involved.
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